HUE066907T2 - Kiméra és humanizált anti-humán-CTLA4 monoklonális antitestek és alkalmazásaik - Google Patents

Kiméra és humanizált anti-humán-CTLA4 monoklonális antitestek és alkalmazásaik

Info

Publication number
HUE066907T2
HUE066907T2 HUE16876612A HUE16876612A HUE066907T2 HU E066907 T2 HUE066907 T2 HU E066907T2 HU E16876612 A HUE16876612 A HU E16876612A HU E16876612 A HUE16876612 A HU E16876612A HU E066907 T2 HUE066907 T2 HU E066907T2
Authority
HU
Hungary
Prior art keywords
chimeric
applications
monoclonal antibodies
humanized anti
human ctla4
Prior art date
Application number
HUE16876612A
Other languages
English (en)
Hungarian (hu)
Inventor
Yang Liu
Pan Zheng
Martin Devenport
Original Assignee
Oncoc4 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoc4 Inc filed Critical Oncoc4 Inc
Publication of HUE066907T2 publication Critical patent/HUE066907T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HUE16876612A 2015-12-15 2016-12-14 Kiméra és humanizált anti-humán-CTLA4 monoklonális antitestek és alkalmazásaik HUE066907T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562267735P 2015-12-15 2015-12-15
US201662309169P 2016-03-16 2016-03-16
US201662359036P 2016-07-06 2016-07-06

Publications (1)

Publication Number Publication Date
HUE066907T2 true HUE066907T2 (hu) 2024-09-28

Family

ID=59057509

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16876612A HUE066907T2 (hu) 2015-12-15 2016-12-14 Kiméra és humanizált anti-humán-CTLA4 monoklonális antitestek és alkalmazásaik

Country Status (26)

Country Link
US (3) US10618960B2 (OSRAM)
EP (2) EP4374926A3 (OSRAM)
JP (5) JP6858779B2 (OSRAM)
KR (2) KR20250108763A (OSRAM)
CN (2) CN108430499B (OSRAM)
AU (2) AU2016370648B2 (OSRAM)
BR (1) BR112018012113A2 (OSRAM)
CA (1) CA3006984C (OSRAM)
DK (1) DK3389699T5 (OSRAM)
ES (1) ES2979210T3 (OSRAM)
FI (1) FI3389699T3 (OSRAM)
HR (1) HRP20240719T1 (OSRAM)
HU (1) HUE066907T2 (OSRAM)
IL (3) IL296354B2 (OSRAM)
LT (1) LT3389699T (OSRAM)
MX (3) MX2018006925A (OSRAM)
MY (1) MY186974A (OSRAM)
PL (1) PL3389699T3 (OSRAM)
PT (1) PT3389699T (OSRAM)
RS (1) RS65703B1 (OSRAM)
SG (1) SG11201804969PA (OSRAM)
SI (1) SI3389699T1 (OSRAM)
SM (1) SMT202400211T1 (OSRAM)
TW (1) TWI739781B (OSRAM)
WO (1) WO2017106372A1 (OSRAM)
ZA (1) ZA201804077B (OSRAM)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE050750T2 (hu) 2015-05-29 2021-01-28 Agenus Inc CTLA-4 elleni antitestek és eljárások alkalmazásukra
CN116942793A (zh) 2016-09-19 2023-10-27 昂科医药 Cd80和cd86结合蛋白组合物及其用途
EA201991383A1 (ru) 2016-12-07 2019-12-30 Эйдженус Инк. Антитела против ctla-4 и способы их применения
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
AU2018366199A1 (en) * 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
JP2021511812A (ja) * 2018-02-02 2021-05-13 オンコイミューン， インコーポレイテッド がん治療のためのより安全でより効果的な抗ｃｔｌａ４抗体を選択及び設計する方法
CN111699195A (zh) * 2018-02-02 2020-09-22 肿瘤免疫股份有限公司 具有改善的免疫治疗效果但减轻的不良作用的突变体抗ctla-4抗体
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
JP7359785B2 (ja) 2018-06-05 2023-10-11 江蘇康寧杰瑞生物制薬有限公司 二量体及びその使用
EP3617230A1 (en) * 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
EP3898677A1 (en) 2018-12-21 2021-10-27 OSE Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
MX2021007848A (es) 2018-12-27 2021-10-26 Gigagen Inc Proteinas de union a anti-ctla-4 y metodos de uso de las mismas.
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
WO2021122866A1 (en) 2019-12-17 2021-06-24 Ose Immunotherapeutics Bifunctional molecules comprising an il-7 variant
WO2021208838A1 (en) * 2020-04-13 2021-10-21 Biosion Inc. Antibodies binding ctla4 and uses thereof
CA3182368A1 (en) 2020-05-01 2021-11-04 Kashiv Biosciences, Llc An improved process of purification of protein
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
US20240018248A1 (en) 2020-12-02 2024-01-18 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2022169269A1 (ko) * 2021-02-03 2022-08-11 주식회사 유틸렉스 항 ctla-4 항체 및 이의 용도
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
CA3213917A1 (en) 2021-04-09 2022-10-13 Nicolas Poirier New scaffold for bifunctional molecules with improved properties
JP7345889B2 (ja) * 2021-06-17 2023-09-19 株式会社ニューギン 遊技機
CA3234491A1 (en) * 2021-10-08 2023-04-13 Kashiv Biosciences, Llc Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography
EP4392156A4 (en) * 2021-10-08 2025-06-25 Kashiv Biosciences, LLC Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography
KR20240091042A (ko) * 2021-10-29 2024-06-21 롱바이오 파마 (수조우) 컴퍼니 리미티드 분리된 항원 결합 단백질 및 이의 용도
JP2024540152A (ja) 2021-10-29 2024-10-31 オンコシーフォー、インク． 抗ｃｔｌａ－４抗体投与レジメン
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
JP2025525886A (ja) 2022-08-02 2025-08-07 オーエスイー・イミュノセラピューティクス Ｃｄ２８に対する多機能性分子
CN119947752A (zh) 2022-09-16 2025-05-06 昂科医药 抗ctla-4抗体用于治疗腺样囊性癌的用途
CN120981564A (zh) 2023-03-17 2025-11-18 圭尔医疗有限公司 调节性t细胞疗法
WO2024200820A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
WO2024200823A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
AU2024262223A1 (en) 2023-04-28 2025-11-27 Acroimmune Biopharma Co., Ltd. Combinations of anti-ctla-4 antibodies and anti-pd-1 antibodies and therapeutic uses thereof
WO2024254403A2 (en) * 2023-06-09 2024-12-12 The Regents Of The University Of California Methods for identifying and correcting tumor humoral immune dysfunction
WO2025133186A1 (en) 2023-12-22 2025-06-26 OncoC4, Inc. Anti-ctla-4 antibody for treatment of patients with prostate cancer and combination therapy with a radioligand therapeutic agent
WO2025201659A1 (en) 2024-03-28 2025-10-02 BioNTech SE Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP2360254A1 (en) 1999-08-23 2011-08-24 Dana-Farber Cancer Institute, Inc. Assays for screening anti-pd-1 antibodies and uses thereof
DE60033293D1 (de) 1999-08-23 2007-03-22 Dana Farber Cancer Inst Inc Neue b7-4 moleküle und deren verwendungen
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
AU784634B2 (en) 1999-11-30 2006-05-18 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
WO2001054732A1 (en) 2000-01-27 2001-08-02 Genetics Institute, Llc. Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
WO2002086083A2 (en) 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
WO2006029220A2 (en) * 2004-09-08 2006-03-16 Ohio State University Research Foundation Combination therapy with anti-ctla4 and anti-4-1bb antibodies
EP1793858A4 (en) * 2004-09-08 2008-12-10 Univ Ohio State Res Found HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT
JP4938673B2 (ja) 2004-10-15 2012-05-23 ベリサイン・インコーポレイテッド ワンタイムパスワード
SG158919A1 (en) * 2005-01-24 2010-02-26 Univ Texas Constructs binding to phosphatidylserine and their use in disease treatment
DK2161336T4 (en) * 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
RS54271B1 (sr) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
US8062852B2 (en) 2007-10-01 2011-11-22 The Children's Hospital And Regional Medical Center Detection and treatment of autoimmune disorders
CN101628940B (zh) * 2008-07-15 2011-11-23 中国科学院生物物理研究所 一种单克隆抗体及其应用
GB0903325D0 (en) * 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
WO2013142796A2 (en) * 2012-03-23 2013-09-26 Bristol-Myers Squibb Company Methods of treatments using ctla4 antibodies
PL2925350T3 (pl) * 2012-12-03 2019-07-31 Bristol-Myers Squibb Company Zwiększenie aktywności przeciwnowotworowej immunomodulacyjnych białek fuzyjnych fc
WO2014209804A1 (en) * 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN104292334B (zh) * 2014-04-25 2018-11-27 河南省健康伟业生物医药研究股份有限公司 一种全人源抗ctla-4单克隆抗体、制备方法及应用
CN116942793A (zh) 2016-09-19 2023-10-27 昂科医药 Cd80和cd86结合蛋白组合物及其用途

Also Published As

Publication number Publication date
FI3389699T3 (fi) 2024-05-28
JP2019510733A (ja) 2019-04-18
US20200283526A1 (en) 2020-09-10
IL259988B (en) 2022-10-01
KR102830926B1 (ko) 2025-07-08
DK3389699T3 (da) 2024-05-13
MY186974A (en) 2021-08-26
ES2979210T3 (es) 2024-09-24
RS65703B1 (sr) 2024-07-31
EP4374926A3 (en) 2024-08-07
EP3389699A1 (en) 2018-10-24
PL3389699T3 (pl) 2024-07-22
HRP20240719T1 (hr) 2024-09-13
IL296354B1 (en) 2024-03-01
KR20180086219A (ko) 2018-07-30
MX2025001300A (es) 2025-03-07
US20190127468A1 (en) 2019-05-02
SG11201804969PA (en) 2018-07-30
IL259988A (en) 2018-07-31
DK3389699T5 (da) 2024-09-23
IL310404A (en) 2024-03-01
JP7286845B2 (ja) 2023-06-05
JP6858779B2 (ja) 2021-04-14
PT3389699T (pt) 2024-06-04
IL259988B2 (en) 2023-02-01
US20230391870A1 (en) 2023-12-07
NZ743013A (en) 2025-03-28
AU2016370648B2 (en) 2023-03-09
SMT202400211T1 (it) 2024-07-09
JP2025160458A (ja) 2025-10-22
CN108430499B (zh) 2022-07-19
MX2025001302A (es) 2025-03-07
SI3389699T1 (sl) 2024-07-31
CA3006984A1 (en) 2017-06-22
JP2021100957A (ja) 2021-07-08
EP3389699A4 (en) 2019-07-10
JP2022123049A (ja) 2022-08-23
AU2023203169A1 (en) 2023-06-15
AU2016370648A1 (en) 2018-06-21
LT3389699T (lt) 2024-06-10
BR112018012113A2 (pt) 2018-12-04
US11629188B2 (en) 2023-04-18
US10618960B2 (en) 2020-04-14
JP2023106547A (ja) 2023-08-01
KR20250108763A (ko) 2025-07-15
IL296354A (en) 2022-11-01
EP3389699B1 (en) 2024-05-01
TWI739781B (zh) 2021-09-21
WO2017106372A1 (en) 2017-06-22
JP7790837B2 (ja) 2025-12-23
AU2023203169B2 (en) 2025-11-27
EP4374926A2 (en) 2024-05-29
MX2018006925A (es) 2018-08-01
CN116063492A (zh) 2023-05-05
CN108430499A (zh) 2018-08-21
ZA201804077B (en) 2019-09-25
CA3006984C (en) 2023-10-17
TW201731877A (zh) 2017-09-16
IL296354B2 (en) 2024-07-01
US12473362B2 (en) 2025-11-18

Similar Documents

Publication Publication Date Title
HUE066907T2 (hu) Kiméra és humanizált anti-humán-CTLA4 monoklonális antitestek és alkalmazásaik
IL283812B (en) Humanized antibody against human pd–1
EP3426686C0 (en) Humanized Anti-PACAP Antibodies and Their Uses
PL3307322T3 (pl) Humanizowane przeciwciała anty-cd40 i ich zastosowania
IL257679B (en) Humanized anti-human cd19 antibodies and methods of use
ZA201701920B (en) Anti-human il-17 monoclonal antibodies and use thereof
IL281272A (en) Humanized antibodies against C5 and their uses
DK3441086T3 (da) Monoklonalt anti-PD-1-antistof
IL263936A (en) Humanized monoclonal antibodies targeting hptp-beta)ve-ptp)
EP3466974A4 (en) HUMANIZED MONOCLONAL ANTI-HUMAN PD-1 ANTIBODY AND USE THEREOF
PT3286223T (pt) Recetores de antigénio quimérico do antigénio do mieloma kappa e suas utilizações
KR20180085002A (ko) 인간화된 항-cll-1 항체
ZA201807167B (en) Humanized anti-il-1r3 antibodies
IL282756A (en) Humanized antibodies against SIRPα
IL248402A0 (en) Humanized antibodies against ceacam1
EP3103811A4 (en) Anti-tissue factor monoclonal antibody
EP3131917A4 (en) Humanized and chimeric monoclonal antibodies to cd99
EP3567053A4 (en) ANTI-CLAUDINE-2 MONOCLONAL ANTIBODY
ITUB20155097A1 (it) Anticorpi umanizzati anti-BAG3
EP3891180C0 (en) HUMANIZED ANTIBODIES AGAINST IL17BR
EP3471762A4 (en) HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODIES DIRECTED AGAINST CD81
HK40092659A (zh) 嵌合和人源化抗人类ctla4单克隆抗体和其用途
HK1255635A1 (zh) 人源化或嵌合的cd3抗体